<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51807">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01720030</url>
  </required_header>
  <id_info>
    <org_study_id>Levosimendan in AKI Study</org_study_id>
    <nct_id>NCT01720030</nct_id>
  </id_info>
  <brief_title>Levosimendan in Acute Kidney Injury Study</brief_title>
  <acronym>LAKIS</acronym>
  <official_title>Prospective, Randomized, Monocenter, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Levosimendan in Intensive Care Patients With Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VieCuri Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VieCuri Medical Centre</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesise that levosimendan will have a positive influence on renal function during
      acute kidney injury in adult intensive care patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to evaluate whether the use of levosimendan is able to improve
      renal function.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in renal function</measure>
    <time_frame>Baseline and every 24 hours until end ICU stay</time_frame>
    <safety_issue>No</safety_issue>
    <description>Daily analysis of kidney function expressed in endogenous creatinine clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Survival of included AKI patients in our ICU measured at day 28</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Conventional therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care as protocolized locally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group receives standard treatment supplemented by levosimendan  (0.2 Âµg/kg/min) for 24 hours within 36 hrs following onset of AKI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Verum therapy</description>
    <arm_group_label>Levosimendan</arm_group_label>
    <other_name>Simdax (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional therapy</intervention_name>
    <description>Placebo therapy to safeguard blinding</description>
    <arm_group_label>Conventional therapy</arm_group_label>
    <other_name>Standard care plus placebo comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed adult patients with AKI

        Exclusion Criteria:

          -  Failure to obtain written consent to participate from patient or legal representative
             (by deferred consent)

          -  Patients entering the ICU for post-operative observation with an estimated length of
             stay less than 24 hrs.

          -  Moribund patients

          -  Patients under the age of 18

          -  Pregnancy

          -  Patients suffering from pre-existing renal failure (elevated NGAL values without
             apparent rise in creatinine values)

          -  Renal replacement therapy initiated before admission due to Chronic Kidney Disease

          -  Hypersensitivity to levosimendan experienced by previous treatments

          -  Severe hypotension and tachycardia

          -  Significant mechanical obstruction affecting ventricular filling or outflow or both.

          -  Severe hepatic impairment (ALAT/ASAT&gt;400U/L)

          -  Patients will be excluded if the treating physician judges that study participation
             is undesirable for medical, medical-ethical or other reasons

          -  Known history of Torsades de Pointes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jos Le Noble, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VieCuri Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VieCuri Medical Center</name>
      <address>
        <city>Venlo</city>
        <state>Limburg</state>
        <zip>NL-5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jos le Noble, MD, Ph.D</last_name>
      <phone>+31 (0)77-3205785</phone>
      <email>jlenoble@viecuri.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>October 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VieCuri Medical Centre</investigator_affiliation>
    <investigator_full_name>Dr. Jos le Noble</investigator_full_name>
    <investigator_title>PhD, MD</investigator_title>
  </responsible_party>
  <keyword>Renal</keyword>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>AKI</keyword>
  <keyword>Levosimendan</keyword>
  <keyword>Simdax</keyword>
  <keyword>Renal perfusion</keyword>
  <keyword>Mortality</keyword>
  <keyword>Renal flow</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
